ES2555167T3 - Nuevos derivados de indol sustituidos como moduladores de gamma secretasa - Google Patents
Nuevos derivados de indol sustituidos como moduladores de gamma secretasa Download PDFInfo
- Publication number
- ES2555167T3 ES2555167T3 ES12733754.1T ES12733754T ES2555167T3 ES 2555167 T3 ES2555167 T3 ES 2555167T3 ES 12733754 T ES12733754 T ES 12733754T ES 2555167 T3 ES2555167 T3 ES 2555167T3
- Authority
- ES
- Spain
- Prior art keywords
- substituents
- group
- hydrogen
- alkyloxy
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VHNYOQKVZQVBLC-RTCGXNAVSA-N (4r,7e,9as)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one Chemical compound C1([C@@H]2COC[C@@H]3CC\C(C(N32)=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC(F)=C(F)C(F)=C1 VHNYOQKVZQVBLC-RTCGXNAVSA-N 0.000 title 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000002475 indoles Chemical class 0.000 title 1
- 229940124648 γ-Secretase Modulator Drugs 0.000 title 1
- -1 NR7R8 Chemical group 0.000 abstract description 62
- 150000001875 compounds Chemical class 0.000 abstract description 58
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 45
- 239000001257 hydrogen Substances 0.000 abstract description 45
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 41
- 125000003545 alkoxy group Chemical group 0.000 abstract description 40
- 125000004093 cyano group Chemical group *C#N 0.000 abstract description 40
- 125000001424 substituent group Chemical group 0.000 abstract description 32
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 30
- 150000003839 salts Chemical class 0.000 abstract description 29
- 125000005843 halogen group Chemical group 0.000 abstract description 26
- 125000004076 pyridyl group Chemical group 0.000 abstract description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 17
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract description 16
- 229910052731 fluorine Inorganic materials 0.000 abstract description 14
- 239000011737 fluorine Chemical group 0.000 abstract description 14
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract description 13
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract description 13
- 125000003226 pyrazolyl group Chemical group 0.000 abstract description 12
- 239000012453 solvate Substances 0.000 abstract description 12
- 125000000753 cycloalkyl group Chemical group 0.000 abstract description 10
- 125000001153 fluoro group Chemical group F* 0.000 abstract description 10
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 abstract description 8
- 125000002883 imidazolyl group Chemical group 0.000 abstract description 8
- 125000002971 oxazolyl group Chemical group 0.000 abstract description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 6
- 125000002757 morpholinyl group Chemical group 0.000 abstract description 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract description 4
- 102100024650 Carbonic anhydrase 3 Human genes 0.000 description 52
- 101000760630 Homo sapiens Carbonic anhydrase 3 Proteins 0.000 description 52
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 41
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 22
- 230000003287 optical effect Effects 0.000 description 20
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000002285 radioactive effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000011324 bead Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 238000006069 Suzuki reaction reaction Methods 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- DACWQSNZECJJGG-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyridine Chemical compound C1=CC=CN2N=CN=C21 DACWQSNZECJJGG-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- YHYLDEVWYOFIJK-UHFFFAOYSA-N 1h-indole-5-carbonitrile Chemical compound N#CC1=CC=C2NC=CC2=C1 YHYLDEVWYOFIJK-UHFFFAOYSA-N 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- PIAWXNKEFFYUCD-UHFFFAOYSA-N 2-[8-(2-cyclopropylphenyl)-6,8-dihydro-5h-imidazo[2,1-c][1,4]oxazin-2-yl]-4-methoxy-1h-indole-5-carbonitrile Chemical compound C=1C=2C(OC)=C(C#N)C=CC=2NC=1C(N=C12)=CN1CCOC2C1=CC=CC=C1C1CC1 PIAWXNKEFFYUCD-UHFFFAOYSA-N 0.000 description 2
- UMAUKBQUICMSGM-UHFFFAOYSA-N 2-[8-(4-fluoro-2-methylphenyl)-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazin-2-yl]-4-propan-2-yloxy-1H-indole-5-carbonitrile Chemical compound C=1C=2C(OC(C)C)=C(C#N)C=CC=2NC=1C(=NN1CCO2)N=C1C2C1=CC=C(F)C=C1C UMAUKBQUICMSGM-UHFFFAOYSA-N 0.000 description 2
- HVSDODQLRPYGML-UHFFFAOYSA-N 2-[8-(4-fluoro-2-methylphenyl)-6,8-dihydro-5h-imidazo[2,1-c][1,4]oxazin-2-yl]-4-methoxy-1h-indole-5-carbonitrile Chemical compound C=1C=2C(OC)=C(C#N)C=CC=2NC=1C(N=C12)=CN1CCOC2C1=CC=C(F)C=C1C HVSDODQLRPYGML-UHFFFAOYSA-N 0.000 description 2
- SWVQFTATJKGKJI-UHFFFAOYSA-N 4-methoxy-2-[8-[5-methyl-2-(2,2,2-trifluoroethyl)pyrazol-3-yl]-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl]-1h-indole-5-carbonitrile Chemical compound C=1C=2C(OC)=C(C#N)C=CC=2NC=1C(N=C12)=CN1CCCC2C1=CC(C)=NN1CC(F)(F)F SWVQFTATJKGKJI-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YNDHMPHNXKLPMA-UHFFFAOYSA-N 2-[5-[2-fluoro-5-(trifluoromethyl)phenyl]-5-methyl-6,8-dihydroimidazo[2,1-c][1,4]oxazin-2-yl]-4-methoxy-1h-indole-5-carbonitrile Chemical compound C=1C=2C(OC)=C(C#N)C=CC=2NC=1C(N=1)=CN2C=1COCC2(C)C1=CC(C(F)(F)F)=CC=C1F YNDHMPHNXKLPMA-UHFFFAOYSA-N 0.000 description 1
- GVCNSJONPNQBSI-UHFFFAOYSA-N 2-[8-(2-chloro-6-fluorophenyl)-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazin-2-yl]-4-methoxy-1H-indole-5-carbonitrile Chemical compound C=1C=2C(OC)=C(C#N)C=CC=2NC=1C(=NN1CCO2)N=C1C2C1=C(F)C=CC=C1Cl GVCNSJONPNQBSI-UHFFFAOYSA-N 0.000 description 1
- PJTKIWAFRIDTBK-UHFFFAOYSA-N 2-[8-(2-chloro-6-fluorophenyl)-6,8-dihydro-5h-imidazo[2,1-c][1,4]oxazin-2-yl]-4-methoxy-1h-indole-5-carbonitrile Chemical compound C=1C=2C(OC)=C(C#N)C=CC=2NC=1C(N=C12)=CN1CCOC2C1=C(F)C=CC=C1Cl PJTKIWAFRIDTBK-UHFFFAOYSA-N 0.000 description 1
- CHLUUWQLDURKRV-UHFFFAOYSA-N 2-[8-(2-chlorophenyl)-6,8-dihydro-5h-imidazo[2,1-c][1,4]oxazin-2-yl]-4-methoxy-1h-indole-5-carbonitrile Chemical compound C=1C=2C(OC)=C(C#N)C=CC=2NC=1C(N=C12)=CN1CCOC2C1=CC=CC=C1Cl CHLUUWQLDURKRV-UHFFFAOYSA-N 0.000 description 1
- HKQJKTOVXPJOIC-UHFFFAOYSA-N 2-[8-(2-fluoro-6-methylphenyl)-6,8-dihydro-5h-imidazo[2,1-c][1,4]oxazin-2-yl]-4-methoxy-1h-indole-5-carbonitrile Chemical compound C=1C=2C(OC)=C(C#N)C=CC=2NC=1C(N=C12)=CN1CCOC2C1=C(C)C=CC=C1F HKQJKTOVXPJOIC-UHFFFAOYSA-N 0.000 description 1
- UBJJQXXWGRHIDV-UHFFFAOYSA-N 2-[8-(3-fluoro-2-methylphenyl)-6,8-dihydro-5h-imidazo[2,1-c][1,4]oxazin-2-yl]-4-methoxy-1h-indole-5-carbonitrile Chemical compound C=1C=2C(OC)=C(C#N)C=CC=2NC=1C(N=C12)=CN1CCOC2C1=CC=CC(F)=C1C UBJJQXXWGRHIDV-UHFFFAOYSA-N 0.000 description 1
- XYQDAYZDRBKPNR-UHFFFAOYSA-N 2-[8-(4-fluoro-2-methylphenyl)-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazin-2-yl]-4-methoxy-1H-indole-5-carbonitrile Chemical compound C=1C=2C(OC)=C(C#N)C=CC=2NC=1C(=NN1CCO2)N=C1C2C1=CC=C(F)C=C1C XYQDAYZDRBKPNR-UHFFFAOYSA-N 0.000 description 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 1
- FBKAGWTYLUGJDP-UHFFFAOYSA-N 4-(2,2-difluoroethoxy)-2-[8-(4-fluoro-2-methylphenyl)-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazin-2-yl]-1H-indole-5-carbonitrile Chemical compound CC1=CC(F)=CC=C1C1C2=NC(C=3NC4=CC=C(C(OCC(F)F)=C4C=3)C#N)=NN2CCO1 FBKAGWTYLUGJDP-UHFFFAOYSA-N 0.000 description 1
- FOKVNBQSMNGHLL-UHFFFAOYSA-N 4-ethoxy-2-[8-(4-fluoro-2-methylphenyl)-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazin-2-yl]-1H-indole-5-carbonitrile Chemical compound C=1C=2C(OCC)=C(C#N)C=CC=2NC=1C(=NN1CCO2)N=C1C2C1=CC=C(F)C=C1C FOKVNBQSMNGHLL-UHFFFAOYSA-N 0.000 description 1
- IHCUUUPUTSNNMH-UHFFFAOYSA-N 4-methoxy-2-(5-phenyl-6,8-dihydro-5h-imidazo[2,1-c][1,4]oxazin-2-yl)-1h-indole-5-carbonitrile Chemical compound C=1C=2C(OC)=C(C#N)C=CC=2NC=1C(N=C1COC2)=CN1C2C1=CC=CC=C1 IHCUUUPUTSNNMH-UHFFFAOYSA-N 0.000 description 1
- OTCNEYHBKYYZGC-UHFFFAOYSA-N 4-methoxy-2-[8-[2-(methoxymethyl)phenyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-1H-indole-5-carbonitrile Chemical compound COCC1=CC=CC=C1C1C2=NC(C=3NC4=CC=C(C(OC)=C4C=3)C#N)=NN2CCC1 OTCNEYHBKYYZGC-UHFFFAOYSA-N 0.000 description 1
- PKLALEKIGAUIEA-UHFFFAOYSA-N 4-methoxy-2-[8-[2-(methoxymethyl)phenyl]-6,8-dihydro-5h-imidazo[2,1-c][1,4]oxazin-2-yl]-1h-indole-5-carbonitrile Chemical compound COCC1=CC=CC=C1C1C2=NC(C=3NC4=CC=C(C(OC)=C4C=3)C#N)=CN2CCO1 PKLALEKIGAUIEA-UHFFFAOYSA-N 0.000 description 1
- NFZWXCQYERVPEI-UHFFFAOYSA-N 4-methoxy-2-[8-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazin-2-yl]-1H-indole-5-carbonitrile Chemical compound C=1C=2C(OC)=C(C#N)C=CC=2NC=1C(=NN1CCO2)N=C1C2C1=CC=CC=C1C(F)(F)F NFZWXCQYERVPEI-UHFFFAOYSA-N 0.000 description 1
- ZOVFQRDNBWHWDZ-UHFFFAOYSA-N 4-methoxy-2-[8-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5h-imidazo[2,1-c][1,4]oxazin-2-yl]-1h-indole-5-carbonitrile Chemical compound C=1C=2C(OC)=C(C#N)C=CC=2NC=1C(N=C12)=CN1CCOC2C1=CC=CC=C1C(F)(F)F ZOVFQRDNBWHWDZ-UHFFFAOYSA-N 0.000 description 1
- PBARAUJEVKQDKA-UHFFFAOYSA-N 8-(4-fluoro-2-methylphenyl)-2-[5-(1-methylpyrazol-4-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazine Chemical compound CC1=CC(F)=CC=C1C1C2=NC(C=3NC4=CC=C(N=C4C=3)C3=CN(C)N=C3)=NN2CCO1 PBARAUJEVKQDKA-UHFFFAOYSA-N 0.000 description 1
- XQZDCTKOMDWSTA-UHFFFAOYSA-N 8-(4-fluoro-2-methylphenyl)-2-[5-(2-methylpyridin-4-yl)-1H-indol-2-yl]-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazine Chemical compound C1=NC(C)=CC(C=2C=C3C=C(NC3=CC=2)C2=NN3CCOC(C3=N2)C=2C(=CC(F)=CC=2)C)=C1 XQZDCTKOMDWSTA-UHFFFAOYSA-N 0.000 description 1
- BPXHIQGWNMTLJM-UHFFFAOYSA-N 8-(4-fluoro-2-methylphenyl)-2-[5-(2-methylpyridin-4-yl)-1h-indol-2-yl]-6,8-dihydro-5h-imidazo[2,1-c][1,4]oxazine Chemical compound C1=NC(C)=CC(C=2C=C3C=C(NC3=CC=2)C=2N=C3C(OCCN3C=2)C=2C(=CC(F)=CC=2)C)=C1 BPXHIQGWNMTLJM-UHFFFAOYSA-N 0.000 description 1
- ADALGTFQPOYXOB-UHFFFAOYSA-N 8-(4-fluoro-2-methylphenyl)-2-[5-(4-methylimidazol-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C1=NC(C)=CN1C1=CN=C(NC(=C2)C3=NN4CCCC(C4=N3)C=3C(=CC(F)=CC=3)C)C2=C1 ADALGTFQPOYXOB-UHFFFAOYSA-N 0.000 description 1
- HWWAJUFEKCOKSC-UHFFFAOYSA-N 8-(4-fluoro-2-methylphenyl)-2-[6-(4-methylimidazol-1-yl)-1H-benzimidazol-2-yl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C1=NC(C)=CN1C1=CC=C(NC(=N2)C3=NN4CCCC(C4=N3)C=3C(=CC(F)=CC=3)C)C2=C1 HWWAJUFEKCOKSC-UHFFFAOYSA-N 0.000 description 1
- WVVJNLJORBXYPW-UHFFFAOYSA-N 8-(4-fluoro-2-methylphenyl)-2-[6-(5-methylimidazol-1-yl)-1H-benzimidazol-2-yl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine Chemical compound CC1=CN=CN1C1=CC=C(NC(=N2)C3=NN4CCCC(C4=N3)C=3C(=CC(F)=CC=3)C)C2=C1 WVVJNLJORBXYPW-UHFFFAOYSA-N 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 238000005609 Rosenmund-von Braun cyanation reaction Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11174120 | 2011-07-15 | ||
| EP11174120 | 2011-07-15 | ||
| PCT/EP2012/063667 WO2013010904A1 (en) | 2011-07-15 | 2012-07-12 | Novel substituted indole derivatives as gamma secretase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2555167T3 true ES2555167T3 (es) | 2015-12-29 |
Family
ID=46506432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12733754.1T Active ES2555167T3 (es) | 2011-07-15 | 2012-07-12 | Nuevos derivados de indol sustituidos como moduladores de gamma secretasa |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9115143B2 (enExample) |
| EP (1) | EP2731948B1 (enExample) |
| JP (1) | JP6068464B2 (enExample) |
| KR (1) | KR101913135B1 (enExample) |
| CN (1) | CN103874702B (enExample) |
| AR (1) | AR087182A1 (enExample) |
| AU (1) | AU2012285931B2 (enExample) |
| BR (1) | BR112014000713A2 (enExample) |
| CA (1) | CA2841102C (enExample) |
| EA (1) | EA023045B1 (enExample) |
| ES (1) | ES2555167T3 (enExample) |
| IL (1) | IL230422B (enExample) |
| IN (1) | IN2014MN00258A (enExample) |
| MX (1) | MX2014000626A (enExample) |
| TW (1) | TWI567079B (enExample) |
| WO (1) | WO2013010904A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA019685B1 (ru) | 2009-02-06 | 2014-05-30 | Янссен Фармасьютикалз, Инк. | Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы |
| BRPI1011190A8 (pt) | 2009-05-07 | 2016-11-16 | Janssen Pharmaceuticals Inc | Derivados de indazol e aza-indazol substituídos como moduladores de gama secretase |
| ES2519565T3 (es) | 2009-07-15 | 2014-11-07 | Janssen Pharmaceuticals Inc. | Derivados de triazol e imidazol sustituidos como moduladores de gamma secretasa |
| EP2523949B1 (en) | 2010-01-15 | 2014-08-20 | Janssen Pharmaceuticals Inc. | Novel substituted triazole derivatives as gamma secretase modulators |
| CA2827969A1 (en) | 2011-03-24 | 2012-09-27 | Janssen Pharmaceuticals, Inc. | Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators |
| TWI567079B (zh) | 2011-07-15 | 2017-01-21 | 健生醫藥公司 | 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物 |
| NZ702611A (en) | 2012-05-16 | 2016-10-28 | Cellzome Ltd | Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease |
| EP2738172A1 (en) * | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
| AU2013366668B2 (en) | 2012-12-20 | 2017-07-20 | Janssen Pharmaceutica Nv | Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators |
| ES2612215T3 (es) | 2013-01-17 | 2017-05-12 | Janssen Pharmaceutica, N.V. | Novedosos derivados de pirido-piperazinona sustituidos como moduladores de gamma secretasa |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| MX391344B (es) | 2016-07-30 | 2025-03-21 | Bristol Myers Squibb Co | Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9). |
| KR102519535B1 (ko) | 2016-09-09 | 2023-04-06 | 브리스톨-마이어스 스큅 컴퍼니 | 피리딜 치환된 인돌 화합물 |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| ES2921020T3 (es) | 2017-08-04 | 2022-08-16 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo |
| CN110997656B (zh) | 2017-08-04 | 2023-04-14 | 百时美施贵宝公司 | 用作tlr7/8/9抑制剂的取代的吲哚化合物 |
| RU2020114670A (ru) | 2017-10-11 | 2021-11-12 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения для применения в качестве ингибиторов rip1 киназы |
| CN111448190B (zh) * | 2017-11-14 | 2023-09-26 | 百时美施贵宝公司 | 取代的吲哚化合物 |
| BR112020011668A2 (pt) | 2017-12-15 | 2020-11-17 | Bristol-Myers Squibb Company | compostos de éter de indol substituído |
| FI3728252T3 (fi) | 2017-12-18 | 2023-10-18 | Bristol Myers Squibb Co | 4-atsaindoliyhdisteitä |
| BR112020012084A2 (pt) | 2017-12-19 | 2020-11-24 | Bristol-Myers Squibb Company | compostos de indol substituído úteis como inibidores de tlr |
| WO2019126082A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | 6-azaindole compounds |
| JP7313354B2 (ja) | 2017-12-19 | 2023-07-24 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｌｒ阻害剤として有用なアミド置換されたインドール化合物 |
| CA3085942A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
| BR112020011984A2 (pt) | 2017-12-20 | 2020-11-17 | Bristol-Myers Squibb Company | compostos de amino indol úteis como inibidores de tlr |
| US11299501B2 (en) | 2017-12-20 | 2022-04-12 | Bristol-Myers Squibb Company | Diazaindole compounds |
| US12084461B2 (en) * | 2018-09-03 | 2024-09-10 | Hoffmann-La Roche Inc. | Bicyclic heteroaryl derivatives |
| EP3628669A1 (en) * | 2018-09-28 | 2020-04-01 | GenKyoTex Suisse SA | Novel compounds as nadph oxidase inhibitors |
| ES2963696T3 (es) | 2018-10-24 | 2024-04-01 | Bristol Myers Squibb Co | Compuestos diméricos de indol sustituidos |
| CN112955450A (zh) | 2018-10-24 | 2021-06-11 | 百时美施贵宝公司 | 经取代的吲哚和吲唑化合物 |
| BR112021009443A2 (pt) | 2018-12-13 | 2021-08-17 | F. Hoffmann-La Roche Ag | derivados de 7-fenóxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-di-hidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina e compostos relacionados como moduladores de gama-secretase para o tratamento da doença de alzheimer. |
| EP3965888B1 (en) | 2019-05-09 | 2024-08-21 | Bristol-Myers Squibb Company | Substituted benzimidazolone compounds |
| WO2021067326A1 (en) | 2019-10-01 | 2021-04-08 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| CN114829350B (zh) | 2019-10-04 | 2024-05-28 | 百时美施贵宝公司 | 经取代的咔唑化合物 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0571253T3 (da) * | 1992-05-19 | 1999-07-19 | Adir | Benzimidazolderivater med antidiabetisk og antiblodpladekoagulerende virkning |
| US5767144A (en) | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
| US6114334A (en) | 1995-07-13 | 2000-09-05 | Knoll Aktiengesellschaft | Piperazine derivatives as therapeutic agents |
| YU86801A (sh) | 1999-06-10 | 2004-07-15 | Warner-Lambert Company | Izoindol derivati korisni u inhibiciji agregacije amiloidnih proteina i snimanju amiloidnih naslaga |
| JP2003530437A (ja) | 2000-04-13 | 2003-10-14 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | Ａβ４２低下物質 |
| US20030176454A1 (en) | 2000-05-15 | 2003-09-18 | Akira Yamada | N-coating heterocyclic compounds |
| DE10109867A1 (de) | 2001-03-01 | 2002-09-05 | Abbott Gmbh & Co Kg | Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie |
| DE10238002A1 (de) | 2002-08-20 | 2004-03-04 | Merck Patent Gmbh | Benzimidazolderivate |
| BRPI0407913A (pt) | 2003-02-27 | 2006-03-01 | Hoffmann La Roche | antagonistas receptores de ccr-3 |
| WO2004110350A2 (en) | 2003-05-14 | 2004-12-23 | Torreypines Therapeutics, Inc. | Compouds and uses thereof in modulating amyloid beta |
| AU2004265101B2 (en) | 2003-08-14 | 2009-06-11 | F. Hoffmann-La Roche Ag | Gabanergic modulators |
| DE602005023965D1 (de) | 2004-03-08 | 2010-11-18 | Prosidion Ltd | Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase |
| RU2361872C2 (ru) | 2004-05-26 | 2009-07-20 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Циннамидное соединение |
| DE602005019602D1 (de) | 2004-10-26 | 2010-04-08 | Eisai R&D Man Co Ltd | Amorphe form einer zimtsäureamidverbindung |
| US20060223849A1 (en) | 2005-03-14 | 2006-10-05 | Mjalli Adnan M | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| BRPI0616150A2 (pt) | 2005-09-22 | 2011-06-07 | Sanofi Aventis | derivados de amino-alquil-amida como lìquidos receptores de ccr3 |
| WO2007043786A1 (en) | 2005-10-10 | 2007-04-19 | Seiyang Yang | Dynamic-based verification apparatus for verification from electronic system level to gate level, and verification method using the same |
| CN101283031B (zh) | 2005-10-11 | 2012-10-10 | 科聚亚公司 | 二芳基胺 |
| US20070117804A1 (en) | 2005-11-10 | 2007-05-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| CA2643055A1 (en) | 2006-03-13 | 2007-09-20 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
| GB0606774D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
| US7893058B2 (en) | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| JP2010511019A (ja) | 2006-12-01 | 2010-04-08 | ガラパゴス・ナムローゼ・フェンノートシャップ | 変性疾患及び炎症性疾患の治療に有用なイミダゾロピリジン化合物 |
| US20100016341A1 (en) | 2006-12-12 | 2010-01-21 | Zhaoning Zhu | Aspartyl protease inhibitors containing a tricyclic ring system |
| CN101631786A (zh) | 2006-12-20 | 2010-01-20 | 先灵公司 | 新颖的jnk抑制剂 |
| JP2010518080A (ja) | 2007-02-08 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療薬 |
| US8252803B2 (en) | 2007-02-12 | 2012-08-28 | Merck Sharp & Dohme Corp. | Piperidine derivatives |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| RU2009144998A (ru) | 2007-05-07 | 2011-06-20 | Шеринг Корпорейшн (US) | Модуляторы гамма-секретазы |
| KR101138045B1 (ko) | 2007-05-11 | 2012-04-24 | 에프. 호프만-라 로슈 아게 | 아밀로이드 베타에 대한 조절제로서의 헤트아릴아닐린 |
| EP2166854A4 (en) | 2007-06-13 | 2012-05-16 | Merck Sharp & Dohme | TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS |
| CL2008001914A1 (es) | 2007-06-29 | 2009-07-17 | Schering Corp | Compuestos heterociclicos de nitrogeno y oxigeno,moduladores de gama secretasa, composicion farmaceutica de dichos compuestos; kit farmaceutico y su uso para prevenir o tratar enfermedades asociadas al sistema nervioso central como alzheimer, sindrome de down, enfermedades neurodegenerativas, inhibir el deposito de proteina amiloide. |
| US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
| US8518975B2 (en) | 2007-09-06 | 2013-08-27 | Merck Sharp + Dohme Corp. | Gamma secretase modulators |
| GB0720444D0 (en) | 2007-10-18 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
| US8450343B2 (en) * | 2007-12-06 | 2013-05-28 | Xianhai Huang | Gamma secretase modulators |
| EP2227471A1 (en) | 2007-12-11 | 2010-09-15 | Schering Corporation | Gamma secretase modulators |
| JP5328816B2 (ja) | 2008-02-22 | 2013-10-30 | エフ．ホフマン−ラ ロシュ アーゲー | アミロイドβの調節薬 |
| US20100137320A1 (en) | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
| WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| CA2738929A1 (en) | 2008-10-17 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as mmp-13 inhibitors |
| AU2009313527A1 (en) | 2008-11-06 | 2010-05-14 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| AU2009312856A1 (en) | 2008-11-10 | 2010-05-14 | F. Hoffmann-La Roche Ag | Heterocyclic gamma secretase modulators |
| AU2009322774A1 (en) | 2008-12-03 | 2011-06-30 | Via Pharmaceuticals, Inc | Inhibitors of diacylglycerol acyltransferase |
| PA8854101A1 (es) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
| TW201030002A (en) | 2009-01-16 | 2010-08-16 | Bristol Myers Squibb Co | Bicyclic compounds for the reduction of beta-amyloid production |
| EA019685B1 (ru) | 2009-02-06 | 2014-05-30 | Янссен Фармасьютикалз, Инк. | Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| JP2012051806A (ja) * | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | イミダゾリルピラジン誘導体 |
| JP2012051807A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | アリールイミダゾール化合物 |
| CA2753696A1 (en) * | 2009-02-26 | 2010-09-02 | Noritaka Kitazawa | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors |
| CA2751534A1 (en) | 2009-03-03 | 2010-09-10 | Pfizer Inc. | Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators |
| EP2410529A1 (en) | 2009-03-16 | 2012-01-25 | Panasonic Corporation | Application running device |
| WO2010114971A1 (en) * | 2009-04-03 | 2010-10-07 | Sepracor Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| AU2010241929A1 (en) * | 2009-04-27 | 2011-10-06 | High Point Pharmaceuticals, Llc | Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors |
| BRPI1011190A8 (pt) | 2009-05-07 | 2016-11-16 | Janssen Pharmaceuticals Inc | Derivados de indazol e aza-indazol substituídos como moduladores de gama secretase |
| JP2010274429A (ja) | 2009-05-26 | 2010-12-09 | Ihi Corp | アライメントステージ |
| ES2519565T3 (es) | 2009-07-15 | 2014-11-07 | Janssen Pharmaceuticals Inc. | Derivados de triazol e imidazol sustituidos como moduladores de gamma secretasa |
| EP2523949B1 (en) | 2010-01-15 | 2014-08-20 | Janssen Pharmaceuticals Inc. | Novel substituted triazole derivatives as gamma secretase modulators |
| WO2012061342A2 (en) * | 2010-11-01 | 2012-05-10 | Arqule, Inc. | Substituted benzo-imidazo-pyrido-diazepine compounds |
| CA2827969A1 (en) | 2011-03-24 | 2012-09-27 | Janssen Pharmaceuticals, Inc. | Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators |
| CA2830027C (en) | 2011-03-31 | 2016-04-26 | Pfizer Inc. | Novel bicyclic pyridinones |
| TWI567079B (zh) | 2011-07-15 | 2017-01-21 | 健生醫藥公司 | 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物 |
-
2012
- 2012-07-12 TW TW101125035A patent/TWI567079B/zh not_active IP Right Cessation
- 2012-07-12 AU AU2012285931A patent/AU2012285931B2/en not_active Ceased
- 2012-07-12 ES ES12733754.1T patent/ES2555167T3/es active Active
- 2012-07-12 MX MX2014000626A patent/MX2014000626A/es unknown
- 2012-07-12 CN CN201280034912.XA patent/CN103874702B/zh not_active Expired - Fee Related
- 2012-07-12 EA EA201490287A patent/EA023045B1/ru not_active IP Right Cessation
- 2012-07-12 BR BR112014000713A patent/BR112014000713A2/pt active Search and Examination
- 2012-07-12 JP JP2014519557A patent/JP6068464B2/ja not_active Expired - Fee Related
- 2012-07-12 US US14/233,078 patent/US9115143B2/en not_active Expired - Fee Related
- 2012-07-12 CA CA2841102A patent/CA2841102C/en not_active Expired - Fee Related
- 2012-07-12 WO PCT/EP2012/063667 patent/WO2013010904A1/en not_active Ceased
- 2012-07-12 EP EP12733754.1A patent/EP2731948B1/en active Active
- 2012-07-12 IN IN258MUN2014 patent/IN2014MN00258A/en unknown
- 2012-07-12 KR KR1020147003465A patent/KR101913135B1/ko not_active Expired - Fee Related
- 2012-07-13 AR ARP120102548A patent/AR087182A1/es not_active Application Discontinuation
-
2014
- 2014-01-13 IL IL230422A patent/IL230422B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| TW201315736A (zh) | 2013-04-16 |
| NZ619683A (en) | 2015-01-30 |
| EP2731948A1 (en) | 2014-05-21 |
| CN103874702A (zh) | 2014-06-18 |
| EA023045B1 (ru) | 2016-04-29 |
| BR112014000713A2 (pt) | 2017-01-10 |
| KR101913135B1 (ko) | 2018-10-30 |
| JP2014518286A (ja) | 2014-07-28 |
| CA2841102A1 (en) | 2013-01-24 |
| MX2014000626A (es) | 2014-04-30 |
| KR20140063595A (ko) | 2014-05-27 |
| TWI567079B (zh) | 2017-01-21 |
| AU2012285931B2 (en) | 2017-01-12 |
| US9115143B2 (en) | 2015-08-25 |
| AR087182A1 (es) | 2014-02-26 |
| EP2731948B1 (en) | 2015-09-09 |
| US20140148450A1 (en) | 2014-05-29 |
| IN2014MN00258A (enExample) | 2015-09-25 |
| CN103874702B (zh) | 2015-12-09 |
| WO2013010904A1 (en) | 2013-01-24 |
| EA201490287A1 (ru) | 2014-05-30 |
| JP6068464B2 (ja) | 2017-01-25 |
| CA2841102C (en) | 2019-08-13 |
| IL230422B (en) | 2018-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2555167T3 (es) | Nuevos derivados de indol sustituidos como moduladores de gamma secretasa | |
| US12152032B2 (en) | Heterocyclic compounds and uses thereof | |
| ES2983003T3 (es) | Compuestos heterocíclicos y heteroarílicos para el tratamiento de la enfermedad de Huntington | |
| JP6510068B2 (ja) | 新規なビフェニル化合物又はその塩 | |
| ES2805087T3 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la cinasa RET | |
| AU2023233205A1 (en) | SHP2 phosphatase inhibitors and methods of use thereof | |
| WO2025080946A2 (en) | Ras inhibitors | |
| TW202124383A (zh) | 醫藥化合物 | |
| AU2025226693A1 (en) | Monoacylglycerol lipase modulators | |
| TW201827431A (zh) | Rip1激酶抑制劑及其使用方法 | |
| EA031601B1 (ru) | Ингибиторы syk | |
| EA029542B1 (ru) | ПРОИЗВОДНЫЕ 4Н-ПИРИДО[1,2-а]ПИРИМИДИН-4-ОНА ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ | |
| US20170008877A1 (en) | Bicyclic lactams and methods of use thereof | |
| JP2020527174A (ja) | Ａｔｒキナーゼの複素環式阻害剤 | |
| US20230219965A1 (en) | Nitrogen-containing fused bicyclic compounds and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors | |
| JP2025538097A (ja) | がんを処置するための方法 | |
| KR20230107419A (ko) | 암 치료 방법 | |
| WO2021074279A1 (en) | Spiro-fused tricyclic map4k1 inhibitors | |
| ES3060156T3 (en) | (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer | |
| Perry et al. | Design and synthesis of soluble and cell-permeable PI3Kδ inhibitors for long-acting inhaled administration | |
| ES2793929T3 (es) | Antagonistas de V1a para tratar trastornos del sueño por desplazamiento de fase | |
| AR070073A1 (es) | Derivados de imidazo[1, 2 - a]piridin-2-carboxamidas, intermediarios para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades que implican a los receptores not. | |
| WO2025103502A1 (en) | Compounds and methods of treating cancers | |
| EA035568B1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ | |
| WO2026041008A1 (en) | Maleic acid derivatives and uses thereof |